Vaccine developers move to stay ahead of Covid-19 variants
Though current vaccines show efficacy, work on next-generation iterations against the South Africa variant is under way.
J&J’s Covid-19 vaccine set to become third to US
FDA briefing documents show intriguing findings on asymptomatic prevention, though these are based on small numbers.
Medtech’s haves and have-nots
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
Zimmer ditches slow-growing business to refocus
And the move will shake up the orthopaedic robotics scene.
Cholesterol fears rock Immunovant
Immunovant and other FcRn-players must hope that a potential safety signal turns out to be indication rather than class specific.
Sputnik V fails to come in from the cold
The Russian-made vaccine posts competitive phase III data – but not on the easily stored formulation.
